A
Alkermes plc (ALKS)
NMS – Real Time Price. Currency in USD
38.29
+2.82 (7.95%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
38.29
+2.82 (7.95%)
At close: May 12, 2026, 4:00 PM EDT
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Name | Position |
|---|---|
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer |
| Mr. Blair C. Jackson | Executive VP, Chief Risk Officer & COO |
| Mr. Christian Todd Nichols | Senior VP & Chief Commercial Officer |
| Mr. David Joseph Gaffin J.D. | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary |
| Mr. Joshua Reed M.B.A. | Senior VP & CFO |
| Mr. Richard F. Pops | Chairman & CEO |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance |
| Mr. Stephen Schiavo | Senior VP & Chief Human Resources Officer |
| Mr. Tom Skoff | SVP & Chief Information Officer |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 8-K | alks-20260512.htm |
| 2026-05-05 | 8-K | alks-20260505.htm |
| 2026-05-01 | 8-K/A | alks-20260212.htm |
| 2026-04-06 | DEF 14A | alks-alks_2026_def_14a.pdf |
| 2026-03-27 | PRE 14A | alks-20260327.htm |
| 2026-02-25 | 10-K | alks-20251231.htm |
| 2026-02-12 | 8-K | d43532d8k.htm |
| 2026-01-12 | 8-K | alks-20260112.htm |
| 2026-01-06 | 8-K | alks-20260106.htm |
| 2025-11-19 | 8-K | d858713d8k.htm |